Deceased, n=3 (N) | Full recovery, n=28 (N) | Resolved, with sequelae, n=3 (N) | |
Sex | |||
Female | 1 (RA+SjS) | 21 | 3 |
Male | 2 (RA, SSc) | 7 | |
Age, median (IQR) | >80 (SSc) >70 (RA, RA+SjS) | 58 (49.5–65.0) | 50 (49–61) |
Rheumatic disease diagnoses | |||
ANCA-associated vasculitis | 2 | ||
Axial spondyloarthritis | 7 | 1 | |
Giant cell arteritis | 1 | ||
Inflammatory myopathy | 1 | ||
Polymyalgia rheumatica | 1 | ||
RA | 1 | 11 | 2 |
Sjogren’s syndrome | 1 | ||
RA+Sjogren’s syndrome | 1 | ||
Systemic lupus erythematosus | 2 | ||
SSc | 1 | 2 | |
Undifferentiated connective tissue disease | 1 | ||
Other | 1 | ||
Rheumatic disease activity | |||
Remission | 16 | ||
Low | 2 (RA, RA+SjS) | 9 | 1 |
Moderate | 1 (SSc) | 3 | |
Unknown | 2 | ||
COVID-19 vaccine type | |||
Pfizer/BioNTech | 3 | 22 | 2 |
Moderna | 1 | ||
AstraZeneca/Oxford | 3 | ||
CoronaVac/Sinovac | 2 | 1 | |
Other | 1 | ||
COVID-19 vaccination status | |||
Partially vaccinated | 1 (SSc) | 20 | 3 |
Fully vaccinated | 2 (RA, RA+SjS) | 8 | |
Rheumatic disease medication | |||
None | 4 | ||
Abatacept | 1 | ||
Antimalarials | 4 | ||
Cyclosporine | 1 | ||
Denosumab | 1 | ||
Glucocorticoids | 1 (RA) | 8 | |
IL-6 inhibitors | 1 | 1 | |
IVIG | 1 | ||
JAK inhibitors | 2 | ||
Methotrexate | 9 | ||
MMF | 2 | ||
MMF+glucocorticoids | 1 (SSc) | ||
Rituximab | 1 (RA+SjS) | ||
Sulfasalazine | 1 | 1 | |
TNF inhibitors | 8 | 1 | |
Other | 4 | ||
Number of days from COVID-19 vaccine to infection, median (IQR) | |||
COVID-19 registry (most recent vaccine dose) | 23 (17–30) | ||
COVAX, first dose | 18 (SSc) | 29 (21.5–72.0) | 26 (18–31) |
COVAX, second dose | 22 (RA) 32 (RA+SjS) | 45 (19–58) | 10 (10–10) |
COVAX, third dose | 26.5 (23–30) |
All data are N (%) of the column unless stated otherwise.
ANCA-associated vasculitis, anti-neutrophil cytoplasmic antibody-associated vasculitis; COVID-19, Coronavirus disease 2019; IL-6, Interleukin-6; IVIG, intravenous immunoglobulin; JAK, janus-kinase; MMF, mycophenolate mofetil; RA, rheumatoid arthritis ; SjS, Sjogren's syndrome; SSc, systemic sclerosis; TNF, tumour necrosis factor.